4-Hydroxycoumarin (CAS 1076-38-6) is the parent heterocycle of the 4-hydroxycoumarin class — a bicyclic compound consisting of a fused benzene ring and an α-pyrone system with a hydroxyl group at the 4-position. It serves as the fundamental pharmacophore for all vitamin K antagonist (VKA) anticoagulants, including warfarin, dicoumarol, acenocoumarol, phenprocoumon, and the superwarfarin rodenticides such as brodifacoum. The 4-hydroxy group is irreplaceable for anticoagulant activity: it forms a critical hydrogen bond with the active-site residues of vitamin K epoxide reductase (VKOR), the enzyme responsible for recycling vitamin K in the coagulation cascade. By inhibiting VKOR, 4-hydroxycoumarin derivatives deplete functional vitamin K, thereby blocking the γ-carboxylation of clotting factors II, VII, IX, and X, as well as proteins C and S. Without this post-translational modification, these coagulation factors cannot chelate calcium ions and are rendered biologically inactive, producing the anticoagulant effect. This scaffold has underpinned one of the most widely prescribed oral anticoagulant drug classes globally for over seven decades, with warfarin remaining on the WHO Model List of Essential Medicines.

4-Hydroxycoumarin exists in a keto-enol tautomeric equilibrium between the enolic 4-hydroxycoumarin form and the ketonic 2,4-chromandione form, with the 4-hydroxy tautomer being the thermodynamically favored species in most organic solvents and in the solid state. This tautomerism has profound consequences for chemical reactivity: in the enol form, the O-4 nucleophile can undergo alkylation (Williamson-type ether formation), acylation, sulfonation, or phosphorylation, producing O-functionalized coumarin derivatives. In the chromandione tautomer, the two carbonyl groups at positions 2 and 4 are available for condensation reactions including Knoevenagel, aldol, and Claisen-type condensations. Most critically, the C-3 position is uniquely activated by the combined electronic effects of the adjacent carbonyl group and the push-pull influence of the tautomeric 4-OH/4-keto system. This activation makes C-3 the preferred site for Michael additions, Mannich reactions, and electrophilic substitutions — the very reactions used to introduce the benzyl, aryl, and heterocyclic side chains that differentiate individual anticoagulant drugs. The dual nucleophilic/electrophilic character arising from tautomerism makes 4-hydroxycoumarin an exceptionally versatile reactive intermediate in heterocyclic synthesis.

Beyond its foundational role in anticoagulant synthesis, 4-hydroxycoumarin has significant applications in fluorescent probe development — the inherent coumarin chromophore (λ_max ~280 nm) provides built-in fluorescence that can be tuned through derivatization for biochemical sensors detecting metal ions, reactive oxygen species, pH changes, and enzymatic activities in biological systems. In medicinal chemistry, the 4-hydroxycoumarin scaffold is recognized as a privileged structure for drug discovery, with derivatives demonstrating antibacterial (DNA gyrase and topoisomerase inhibition), antifungal, anticancer (tubulin polymerization inhibition, kinase modulation), anti-inflammatory (COX/LOX pathway inhibition), and antiviral activities. The compound serves as a versatile heterocyclic building block for constructing fused polycyclic systems — chromenoquinolines, pyranocoumarins, and coumarin-annulated heterocycles — via Michael additions, Knoevenagel condensations, and transition-metal-catalyzed cross-coupling reactions. In natural product total synthesis, 4-hydroxycoumarin is the key intermediate for synthesizing dicoumarol, the naturally occurring anticoagulant first isolated from spoiled sweet clover hay, as well as diverse plant-derived coumarins, furanocoumarins, and pyranocoumarins. Finally, 4-hydroxycoumarin is essential for the industrial synthesis of second-generation anticoagulant rodenticides (brodifacoum class) that dominate the global pest-control market due to their single-feeding efficacy and extended duration of action.

4-Hydroxycoumarin should be stored at +2°C to +8°C in a tightly sealed container, protected from light and moisture, under an inert atmosphere — argon or nitrogen is recommended for long-term storage to prevent oxidative degradation. At ambient temperatures and under proper storage conditions, the compound is stable for at least 24 months from the date of manufacture, though exposure to strong bases (which deprotonate the 4-OH and may promote ring-opening or decomposition), strong oxidizing agents, and prolonged heating above the melting point (212-214°C, with decomposition possible above 215°C) should be avoided. As the parent compound of pharmacologically potent anticoagulant agents, 4-hydroxycoumarin should be handled using appropriate personal protective equipment including nitrile gloves, safety goggles, and a laboratory coat, with all manipulations conducted in a well-ventilated area or fume hood. While 4-hydroxycoumarin itself has negligible anticoagulant activity compared to its C-3-substituted derivatives (the C-3 substituent is required for high-affinity VKOR binding), standard chemical hygiene practices must be observed, and ingestion, inhalation, or skin contact should be avoided. UPOR Biotech provides a Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS/SDS), and handling recommendations with every shipment to ensure safe and compliant use.

UPOR Biotech supplies 4-Hydroxycoumarin at Pharmaceutical Intermediate Grade / Research Grade with a minimum HPLC purity of ≥98.0%, accompanied by a comprehensive Certificate of Analysis (CoA) detailing assay results (HPLC), related substances (individual and total impurities), water content (Karl Fischer titration), residual solvents (per ICH Q3C guidelines), heavy metals, loss on drying, ash content, and microbiological limits (total plate count, yeast and mold, specified pathogens). Our manufacturing operations are ISO 9001:2015 certified and conducted under c-GMP (current Good Manufacturing Practice) guidelines, with a Drug Master File (DMF) available to support pharmaceutical clients’ regulatory filings with the US FDA, EMA, and other global health authorities. Additional documentation provided upon request includes a Material Safety Data Sheet (MSDS/SDS), Certificate of Origin, Statement of GMP Compliance, residual solvent declaration, and elemental impurity risk assessment per ICH Q3D. Custom packaging (amber glass or HDPE containers under inert gas, from 1 g research quantities to multi-kilogram production batches), labeling, and specification adjustments are available to meet individual client requirements. Our technical support team can provide analytical method details (HPLC conditions, column specifications, reference standard sourcing), accelerated and long-term stability data, impurity reference standards, and guidance on regulatory filing strategies for ANDA/DMF submissions involving 4-hydroxycoumarin as a starting material or intermediate.